$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000032001723000011 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.665M	$3.370M	$14.14M
YoY Change	9.66%	24.86%	24.37%
% of Gross Profit
Research & Development	$3.179M	$3.170M	$13.07M
YoY Change	-3.02%	-23.61%	-26.09%
% of Gross Profit
Depreciation & Amortization	$30.00K	$50.00K	$69.00K
YoY Change	328.57%	525.0%	-31.0%
% of Gross Profit
Operating Expenses	$6.844M	$6.540M	$57.60M
YoY Change	3.38%	-4.51%	98.28%
Operating Profit	-$6.844M		-$57.60M
YoY Change	3.38%		98.28%
Interest Expense	$670.0K	$560.0K	$1.050M
YoY Change	963.49%	1300.0%	595.36%
% of Operating Profit
Other Income/Expense, Net	$657.0K	-$10.00K	$897.0K
YoY Change	-872.94%	-166.67%	1080.26%
Pretax Income	-$6.187M	-$5.990M	-$56.70M
YoY Change	-7.73%	-11.83%	95.71%
Income Tax	$0.00	$0.00	-$2.479M
% Of Pretax Income
Net Earnings	-$6.187M	-$5.990M	-$54.23M
YoY Change	46.4%	-11.83%	97.43%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.77		-$10.47
Diluted Earnings Per Share	-$0.77	-$0.76	-$10.47
COMMON SHARES
Basic Shares Outstanding	7.998M shares	7.860M shares	5.180M shares
Diluted Shares Outstanding	7.987M shares		5.180M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$61.10M	$69.23M	$69.20M
YoY Change	-30.98%	-27.11%	-27.13%
Cash & Equivalents	$28.16M	$32.15M	$32.20M
Short-Term Investments	$32.94M	$37.07M	$37.10M
Other Short-Term Assets	$4.200M	$2.700M	$2.700M
YoY Change	92.57%	122.77%	122.77%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$65.30M	$71.88M	$71.90M
YoY Change	-28.01%	-25.27%	-25.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$262.0K	$296.0K	$800.0K
YoY Change	376.36%	377.42%	1.78%
Goodwill
YoY Change
Intangibles	$400.0K	$400.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$449.0K	$528.0K	$0.00
YoY Change	-36.58%	-30.89%	-100.0%
Total Long-Term Assets	$1.028M	$1.158M	$1.100M
YoY Change	34.73%	40.19%	33.17%
TOTAL ASSETS
Total Short-Term Assets	$65.30M	$71.88M	$71.90M
Total Long-Term Assets	$1.028M	$1.158M	$1.100M
Total Assets	$66.33M	$73.03M	$73.00M
YoY Change	-27.48%	-24.71%	-24.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.341M	$2.655M	$2.700M
YoY Change	92.4%	37.28%	39.61%
Accrued Expenses	$3.945M	$3.728M	$3.700M
YoY Change	87.5%	43.99%	42.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.286M	$6.383M	$6.400M
YoY Change	88.72%	41.12%	41.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$337.0K	$327.0K	$300.0K
YoY Change	-19.95%	-32.58%	-38.14%
Total Long-Term Liabilities	$337.0K	$327.0K	$300.0K
YoY Change	-19.95%	-32.58%	-38.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.286M	$6.383M	$6.400M
Total Long-Term Liabilities	$337.0K	$327.0K	$300.0K
Total Liabilities	$5.623M	$6.710M	$6.500M
YoY Change	74.52%	33.99%	36.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$513.4M	-$507.2M
YoY Change	12.29%	11.97%
Common Stock	$8.000K	$8.000K
YoY Change	-86.89%	-86.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$708.0K
YoY Change		0.0%
Treasury Stock Shares		738.0 shares
Shareholders Equity	$60.96M	$66.58M	$66.60M
YoY Change
Total Liabilities & Shareholders Equity	$66.33M	$73.03M	$73.00M
YoY Change	-27.48%	-24.71%	-24.75%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$6.187M	-$5.990M	-$54.23M
YoY Change	46.4%	-11.83%	97.43%
Depreciation, Depletion And Amortization	$30.00K	$50.00K	$69.00K
YoY Change	328.57%	525.0%	-31.0%
Cash From Operating Activities	-$8.196M	-$6.470M	-$21.17M
YoY Change	45.27%	40.53%	-4.83%
INVESTING ACTIVITIES
Capital Expenditures		$30.00K	$285.0K
YoY Change			375.0%
Acquisitions
YoY Change
Other Investing Activities	$4.290M	$7.140M	$29.20M
YoY Change	-170.44%	-56.62%	-153.25%
Cash From Investing Activities	$4.289M	$7.100M	$28.91M
YoY Change	-170.43%	-56.86%	-152.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$43.00K
YoY Change			-99.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$85.00K	20.00K	-$224.0K
YoY Change	-49.4%	-4.76%	-100.26%
NET CHANGE
Cash From Operating Activities	-$8.196M	-6.470M	-$21.17M
Cash From Investing Activities	$4.289M	7.100M	$28.91M
Cash From Financing Activities	-$85.00K	20.00K	-$224.0K
Net Change In Cash	-$3.999M	650.0K	$7.507M
YoY Change	-66.39%	-94.53%	-7.72%
FREE CASH FLOW
Cash From Operating Activities	-$8.196M	-$6.470M	-$21.17M
Capital Expenditures		$30.00K	$285.0K
Free Cash Flow		-$6.500M	-$21.46M
YoY Change		41.18%	-3.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	31300000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7998342	shares
CY2022	dei	Auditor Firm AuditorFirmId	248
CY2022	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32154000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	37072000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2650000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	71876000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	296000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	334000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	528000	usd
CY2022Q4	us-gaap	Assets Assets	73034000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2655000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3728000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6383000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	327000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6710000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	clbs	Preferred Stock Liquidation Preference Share PreferredStockLiquidationPreferenceShare	0.000067	shares
CY2021Q4	clbs	Preferred Stock Liquidation Preference Share PreferredStockLiquidationPreferenceShare	0.000067	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2021Q4	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7866799	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3986719	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7866061	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3985981	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	574548000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	546044000	usd
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	738	shares
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	738	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	708000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	708000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-507241000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-453016000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-70000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	66578000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32242000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	92254000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-254000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-254000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66324000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	92000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73034000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97008000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13067000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17576000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	30393000	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14141000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11474000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	57601000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	29050000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-57601000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-29050000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	1052000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	151000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-155000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-75000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	897000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	76000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56704000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28974000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2479000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1508000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.45
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.45
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5180000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5180000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3688000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3688000	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-54225000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-27466000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	52000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-57000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-11000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	41000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-57000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-54184000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-27523000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54184000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27523000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-27466000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1757000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	85500000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-57000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	92000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-54225000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2367000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	43000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26098000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	52000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-11000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-11000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66324000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-54225000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-27466000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2636000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2005000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	55000	usd
CY2022	clbs	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	30393000	usd
CY2021	clbs	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	0	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-788000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2514000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	845000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	453000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-237000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	150000	usd
CY2022	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-223000	usd
CY2021	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	1250000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21170000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22245000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	89687000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	179775000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	122203000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	124939000	usd
CY2022	clbs	Payments For Merger Related Costs Investing Activities PaymentsForMergerRelatedCostsInvestingActivities	3320000	usd
CY2021	clbs	Payments For Merger Related Costs Investing Activities PaymentsForMergerRelatedCostsInvestingActivities	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	285000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28911000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-54896000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	267000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	248000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-224000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85276000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7507000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8135000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24647000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16512000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32154000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24647000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	23580000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	2136000	usd
CY2021	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	usd
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	15
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.5338
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3772768	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1227776	shares
CY2022Q3	clbs	Ownership Of Corporate Stock OwnershipOfCorporateStock	0.52
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger, which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). Accordingly, actual results could differ from those estimates and assumptions.</span></div>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div>
CY2022	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div>
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	400000	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	71000	usd
CY2022Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	36100000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64758000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64740000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	91522000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	70000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	91452000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64740000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	64758000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	64740000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	91522000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	91452000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64758000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64740000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	91522000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	91452000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	142041	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	84.60
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M19D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2021Q4	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	1423774	shares
CY2021Q4	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	42.57
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	713000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	430000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	417000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	368000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	296000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62000	usd
CY2022	us-gaap	Depreciation Depreciation	100000	usd
CY2021	us-gaap	Depreciation Depreciation	100000	usd
CY2021	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P4Y4M13D
CY2021Q4	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	37458	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.49
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2586000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2034000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	180000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	229000	usd
CY2022Q4	clbs	Research And Development Liabilities ResearchAndDevelopmentLiabilities	785000	usd
CY2021Q4	clbs	Research And Development Liabilities ResearchAndDevelopmentLiabilities	0	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	177000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	326000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3728000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2589000	usd
CY2022Q4	clbs	Number Of Offices Under Operating Leases NumberOfOfficesUnderOperatingLeases	2	office
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	487000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	724000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	487000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	724000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	180000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	229000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	305000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	485000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	485000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	714000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09625
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	217000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	190000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	143000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	550000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	65000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	485000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	333333	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1227776	shares
CY2022	clbs	Warrants Granted WarrantsGranted	0	shares
CY2022	clbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1227776	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.77
CY2022	clbs	Warrants Exercised WarrantsExercised	0	shares
CY2022	clbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5844	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.68
CY2022	clbs	Warrants Canceled WarrantsCanceled	0	shares
CY2022	clbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	10079	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	192.41
CY2022	clbs	Warrants Expired WarrantsExpired	0	shares
CY2022	clbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1391352	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	187.6	usd
CY2022Q4	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	1423744	shares
CY2022Q4	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	42.57
CY2022	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P3Y4M13D
CY2022Q4	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1389844	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	187.6	usd
CY2022Q4	clbs	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	1423744	shares
CY2022Q4	clbs	Weighted Average Exercise Price Warrants Vested And Expected To Vest WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest	42.57
CY2022	clbs	Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest	P3Y4M13D
CY2022Q4	clbs	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1145342	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	11.60
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y9M3D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	187.6	usd
CY2022Q4	clbs	Warrants Vested WarrantsVested	1423744	shares
CY2022Q4	clbs	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	42.57
CY2022	clbs	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P3Y4M13D
CY2022Q4	clbs	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2636000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2005000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-56175000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-28974000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-529000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56704000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28974000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2479000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1508000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2479000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1508000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-2479000	usd
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-1508000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2479000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1508000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11908000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6085000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7238000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	320000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	8604000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	622000	usd
CY2022	clbs	Effective Income Tax Rate Reconciliation Tax Reconciliation Amount EffectiveIncomeTaxRateReconciliationTaxReconciliationAmount	1000	usd
CY2021	clbs	Effective Income Tax Rate Reconciliation Tax Reconciliation Amount EffectiveIncomeTaxRateReconciliationTaxReconciliationAmount	-2277000	usd
CY2022	clbs	Effective Income Tax Rate Reconciliation Changein State Deferred Amount EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount	162000	usd
CY2021	clbs	Effective Income Tax Rate Reconciliation Changein State Deferred Amount EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount	0	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-25000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1407000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-21000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	usd
CY2022	clbs	Effective Income Tax Rate Reconciliation Section382 Nol Limitation Amount EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount	18553000	usd
CY2021	clbs	Effective Income Tax Rate Reconciliation Section382 Nol Limitation Amount EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount	35438000	usd
CY2022	clbs	Effective Income Tax Rate Reconciliation Sale Of State Net Operating Losses EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses	-2479000	usd
CY2021	clbs	Effective Income Tax Rate Reconciliation Sale Of State Net Operating Losses EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses	-1508000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-22602000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-33979000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2479000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1508000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13132000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36281000	usd
CY2022Q4	clbs	Deferred Tax Assets Right Of Use Liability DeferredTaxAssetsRightOfUseLiability	136000	usd
CY2021Q4	clbs	Deferred Tax Assets Right Of Use Liability DeferredTaxAssetsRightOfUseLiability	201000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3027000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3086000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	944000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	97000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	5018000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	0	usd
CY2022Q4	clbs	Deferred Tax Assets Accumulated Depreciation DeferredTaxAssetsAccumulatedDepreciation	14000	usd
CY2021Q4	clbs	Deferred Tax Assets Accumulated Depreciation DeferredTaxAssetsAccumulatedDepreciation	26000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	118000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	176000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	579000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	526000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22968000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40393000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	137000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	204000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	99000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	236000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	204000	usd
CY2022Q4	clbs	Net Deferred Tax Assets And Liabilities Gross NetDeferredTaxAssetsAndLiabilitiesGross	22732000	usd
CY2021Q4	clbs	Net Deferred Tax Assets And Liabilities Gross NetDeferredTaxAssetsAndLiabilitiesGross	40189000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22732000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40189000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	112300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	88200000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	34000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	344000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	344000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	344000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	344000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q1	clbs	Proceeds From Sale Of Net Operating Losses Njeda Program Gross ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross	27500000	usd
CY2022Q1	clbs	Proceeds From Sale Of Net Operating Losses Njeda Program ProceedsFromSaleOfNetOperatingLossesNJEDAProgram	2300000	usd
CY2022Q1	clbs	Loss On Sale Of Net Operating Losses LossOnSaleOfNetOperatingLosses	100000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.485
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	700000	usd
CY2021Q4	clbs	Collaborative Arrangement Rights And Obligations Annual License Maintenance Fee After First Sale CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale	150000000	usd

Files In Submission

Name	View Source	Status
clbs-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clbs-20221231_cal.xml	Edgar Link	unprocessable
0000320017-23-000011-index-headers.html	Edgar Link	pending
0000320017-23-000011-index.html	Edgar Link	pending
0000320017-23-000011.txt	Edgar Link	pending
0000320017-23-000011-xbrl.zip	Edgar Link	pending
clbs-20221231.htm	Edgar Link	pending
clbs-20221231.xsd	Edgar Link	pending
clbs-20221231_g1.jpg	Edgar Link	pending
clbs-20221231_def.xml	Edgar Link	unprocessable
clbs-20221231_htm.xml	Edgar Link	completed
clbs-ex311_20221231xq4.htm	Edgar Link	pending
clbs-ex32_20221231.htm	Edgar Link	pending
ex101to10-k20222131.htm	Edgar Link	pending
ex102-lisatatherapeutics.htm	Edgar Link	pending
ex102-lisatatherapeutics001.jpg	Edgar Link	pending
ex102-lisatatherapeutics002.jpg	Edgar Link	pending
ex102-lisatatherapeutics003.jpg	Edgar Link	pending
ex102-lisatatherapeutics004.jpg	Edgar Link	pending
ex102-lisatatherapeutics005.jpg	Edgar Link	pending
ex102-lisatatherapeutics006.jpg	Edgar Link	pending
ex102-lisatatherapeutics007.jpg	Edgar Link	pending
ex102-lisatatherapeutics008.jpg	Edgar Link	pending
ex102-lisatatherapeutics009.jpg	Edgar Link	pending
ex102-lisatatherapeutics010.jpg	Edgar Link	pending
ex102-lisatatherapeutics011.jpg	Edgar Link	pending
ex102-lisatatherapeutics012.jpg	Edgar Link	pending
ex102-lisatatherapeutics013.jpg	Edgar Link	pending
ex102-lisatatherapeutics014.jpg	Edgar Link	pending
ex102-lisatatherapeutics015.jpg	Edgar Link	pending
ex1025clawbackpolicy.htm	Edgar Link	pending
ex1032018equityincentive.htm	Edgar Link	pending
ex1032018equityincentive001.jpg	Edgar Link	pending
ex1032018equityincentive002.jpg	Edgar Link	pending
ex1032018equityincentive003.jpg	Edgar Link	pending
ex1032018equityincentive004.jpg	Edgar Link	pending
ex1032018equityincentive005.jpg	Edgar Link	pending
ex1032018equityincentive006.jpg	Edgar Link	pending
ex1032018equityincentive007.jpg	Edgar Link	pending
ex1032018equityincentive008.jpg	Edgar Link	pending
ex1032018equityincentive009.jpg	Edgar Link	pending
ex1032018equityincentive010.jpg	Edgar Link	pending
ex1032018equityincentive011.jpg	Edgar Link	pending
ex1032018equityincentive012.jpg	Edgar Link	pending
ex1032018equityincentive013.jpg	Edgar Link	pending
ex1032018equityincentive014.jpg	Edgar Link	pending
ex1032018equityincentive015.jpg	Edgar Link	pending
ex1032018equityincentive016.jpg	Edgar Link	pending
ex1032018equityincentive017.jpg	Edgar Link	pending
ex1032018equityincentive018.jpg	Edgar Link	pending
ex1032018equityincentive019.jpg	Edgar Link	pending
ex1032018equityincentive020.jpg	Edgar Link	pending
ex1032018equityincentive021.jpg	Edgar Link	pending
ex1032018equityincentive022.jpg	Edgar Link	pending
ex1032018equityincentive023.jpg	Edgar Link	pending
ex1032018equityincentive024.jpg	Edgar Link	pending
clbs-20221231_pre.xml	Edgar Link	unprocessable
ex1032018equityincentive025.jpg	Edgar Link	pending
ex1032018equityincentive026.jpg	Edgar Link	pending
ex1032018equityincentive027.jpg	Edgar Link	pending
ex1032018equityincentive028.jpg	Edgar Link	pending
ex1032018equityincentive029.jpg	Edgar Link	pending
ex1032018equityincentive030.jpg	Edgar Link	pending
ex1032018equityincentive031.jpg	Edgar Link	pending
ex1032018equityincentive032.jpg	Edgar Link	pending
ex1032018equityincentive033.jpg	Edgar Link	pending
ex1032018equityincentive034.jpg	Edgar Link	pending
ex1032018equityincentive035.jpg	Edgar Link	pending
ex1032018equityincentive036.jpg	Edgar Link	pending
ex1032018equityincentive037.jpg	Edgar Link	pending
ex1032018equityincentive038.jpg	Edgar Link	pending
ex1032018equityincentive039.jpg	Edgar Link	pending
ex1032018equityincentive040.jpg	Edgar Link	pending
ex1032018equityincentive041.jpg	Edgar Link	pending
ex1032018equityincentive042.jpg	Edgar Link	pending
ex1032018equityincentive043.jpg	Edgar Link	pending
ex1032018equityincentive044.jpg	Edgar Link	pending
ex1032018equityincentive045.jpg	Edgar Link	pending
ex1032018equityincentive046.jpg	Edgar Link	pending
ex1032018equityincentive047.jpg	Edgar Link	pending
ex1032018equityincentive048.jpg	Edgar Link	pending
ex1032018equityincentive049.jpg	Edgar Link	pending
ex1032018equityincentive050.jpg	Edgar Link	pending
ex1032018equityincentive051.jpg	Edgar Link	pending
ex1032018equityincentive052.jpg	Edgar Link	pending
ex1032018equityincentive053.jpg	Edgar Link	pending
ex1032018equityincentive054.jpg	Edgar Link	pending
ex104-2015equitycompensa.htm	Edgar Link	pending
ex104-2015equitycompensa001.jpg	Edgar Link	pending
ex104-2015equitycompensa002.jpg	Edgar Link	pending
ex104-2015equitycompensa003.jpg	Edgar Link	pending
ex104-2015equitycompensa004.jpg	Edgar Link	pending
ex104-2015equitycompensa005.jpg	Edgar Link	pending
ex104-2015equitycompensa006.jpg	Edgar Link	pending
ex104-2015equitycompensa007.jpg	Edgar Link	pending
ex104-2015equitycompensa008.jpg	Edgar Link	pending
ex104-2015equitycompensa009.jpg	Edgar Link	pending
ex104-2015equitycompensa010.jpg	Edgar Link	pending
ex104-2015equitycompensa011.jpg	Edgar Link	pending
ex104-2015equitycompensa012.jpg	Edgar Link	pending
ex104-2015equitycompensa013.jpg	Edgar Link	pending
ex104-2015equitycompensa014.jpg	Edgar Link	pending
ex104-2015equitycompensa015.jpg	Edgar Link	pending
ex104-2015equitycompensa016.jpg	Edgar Link	pending
ex104-2015equitycompensa017.jpg	Edgar Link	pending
ex104-2015equitycompensa018.jpg	Edgar Link	pending
ex104-2015equitycompensa019.jpg	Edgar Link	pending
ex104-2015equitycompensa020.jpg	Edgar Link	pending
ex104-2015equitycompensa021.jpg	Edgar Link	pending
ex104-2015equitycompensa022.jpg	Edgar Link	pending
ex104-2015equitycompensa023.jpg	Edgar Link	pending
ex105-amendedrestated200.htm	Edgar Link	pending
ex105-amendedrestated200001.jpg	Edgar Link	pending
ex105-amendedrestated200002.jpg	Edgar Link	pending
ex105-amendedrestated200003.jpg	Edgar Link	pending
ex105-amendedrestated200004.jpg	Edgar Link	pending
ex105-amendedrestated200005.jpg	Edgar Link	pending
ex105-amendedrestated200006.jpg	Edgar Link	pending
ex105-amendedrestated200007.jpg	Edgar Link	pending
ex105-amendedrestated200008.jpg	Edgar Link	pending
ex105-amendedrestated200009.jpg	Edgar Link	pending
ex105-amendedrestated200010.jpg	Edgar Link	pending
ex105-amendedrestated200011.jpg	Edgar Link	pending
ex105-amendedrestated200012.jpg	Edgar Link	pending
ex105-amendedrestated200013.jpg	Edgar Link	pending
ex105-amendedrestated200014.jpg	Edgar Link	pending
ex105-amendedrestated200015.jpg	Edgar Link	pending
ex105-amendedrestated200016.jpg	Edgar Link	pending
ex105-amendedrestated200017.jpg	Edgar Link	pending
ex105-amendedrestated200018.jpg	Edgar Link	pending
ex14110-k20221231.htm	Edgar Link	pending
ex211to10k20221231.htm	Edgar Link	pending
exh2312022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2023 Q1 Form 10-K Financial Statement

#000032001723000011 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2023 Q1 Form 10-K Financial Statement

#000032001723000011 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta